ASX:IMM
ASX:IMMBiotechs

High Growth Tech Stocks To Watch In Australia July 2025

The Australian market has experienced a downward trend recently, influenced by the Reserve Bank of Australia's cautious stance on interest rate cuts and uncertainties surrounding upcoming U.S. tariffs. In this environment, identifying high-growth tech stocks requires careful consideration of their resilience to economic shifts and their potential to capitalize on emerging technological trends.
ASX:NXL
ASX:NXLSoftware

ASX Stocks That May Be Trading Below Their Estimated Value July 2025

The Australian market recently experienced a downward slide as investors reacted to Reserve Bank comments cautioning against expectations of an August rate cut, while global uncertainties such as impending US tariffs add further complexity. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities, especially when considering sectors like Real Estate and Health Care that have shown varied performance.
ASX:ALK
ASX:ALKMetals and Mining

3 Promising ASX Penny Stocks With Market Caps Under A$500M

The Australian stock market has faced a mixed bag of performances, with recent comments from the RBA and global trade tensions influencing investor sentiment. For those exploring opportunities beyond the well-known companies, penny stocks—typically smaller or newer enterprises—remain an intriguing area for potential growth. Despite their vintage name, these stocks can offer surprising value and stability when backed by solid financial foundations.
ASX:ALX
ASX:ALXInfrastructure

The Bull Case For Atlas Arteria (ASX:ALX) Could Change Following Virginia Court Ruling on Dulles Greenway – Learn Why

On 17 July 2025, Atlas Arteria reported that the Supreme Court of Virginia upheld a 2024 decision rejecting a toll rate increase for the Dulles Greenway, and that related federal litigation will now proceed. This development places continued regulatory and legal uncertainty on the Dulles Greenway asset, influencing both its revenue potential and operational stability. We'll explore how ongoing legal challenges regarding toll rates could shape Atlas Arteria's investment narrative in the near...
ASX:MSB
ASX:MSBBiotechs

Mesoblast (ASX:MSB) Is Up 44.1% After Strong Initial Sales of FDA-Approved Ryoncil

Earlier this year, Mesoblast reported robust initial sales for Ryoncil, its first commercial cell therapy product approved by the US FDA last December to treat complications in children following bone marrow transplants. This marks the company's transition from a lengthy development phase to generating its first significant product-based revenue stream in over two decades. We’ll explore how the launch of Ryoncil as a new revenue driver may shape Mesoblast’s broader investment story. AI is...
ASX:M7T
ASX:M7THealthcare Services

ASX Penny Stocks Spotlight Delta Lithium And Two Others

Australian shares are set to open slightly higher, with the ASX 200 futures showing resilience amid global trade discussions, particularly between the U.S. and EU. In this context of international negotiations and market fluctuations, investors may find value in exploring smaller or newer companies that fall under the category of penny stocks—a term that might seem outdated but remains relevant for those seeking unique investment opportunities. These stocks can offer a blend of potential...